Shots:

• The companies collaborated to develop AAV vectors deploying Cure Genetics' VELP platform to develop next-generation gene therapies
• The focus of the pact is to provide new AAV serotypes for patients. The collaboration integrates Boehringer Ingelheim's experience in disease biology and gene therapy development with Cure Genetics' AAV expertise in library construction and in vivo AAV screening
• The VELP technology provides effective solutions in increasing the efficiency of novel AAV screening- further expanding the efforts in the area of gene therapy development

 ­ Ref: PRNewswire | Image: Boehringer Ingelheim